Immunovant, Inc.
NASDAQ:IMVTBiotechnology
Healthcare
$32.52 +2.00%
+$0.69 today
- Market cap
- $6.73B
- Beta
- 0.79
- P/E (TTM)
- -14.3
- EPS (TTM)
- -$2.48
52W Low $14.32High $36.29
Volume 0.73M
Average 1.84M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$407.31M
FY 2026 · Annual
Investing Cash Flow
-$8,000.00
FY 2026 · Annual
Financing Cash Flow
$595.76M
FY 2026 · Annual
+31.1% YoYCash Flow Statement
USD
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (156.73M) | (210.96M) | (259.34M) | (413.84M) | (505.61M) |
| Depreciation & Amortization | 126K | 193K | 231K | 377K | 409K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 34.24M | 32.3M | 41.12M | 49.49M | 55.72M |
| Change in Working Capital | 15.14M | (10.85M) | 2.63M | (12.03M) | 42.06M |
| Accounts Receivables | (11.72M) | 12.23M | (4.56M) | 2.97M | (1.4M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.25M | (17.12M) | 5.78M | 10.68M | (10.25M) |
| Other Working Capital | 10.61M | (5.95M) | 1.41M | (25.69M) | 53.72M |
| Other Non-Cash Items | 1.11M | 1.13M | 1.13M | 133K | 99K |
| Operating Cash Flow | (106.11M) | (188.19M) | (214.23M) | (375.87M) | (407.31M) |
| Capital Expenditures | (254K) | (197K) | (360K) | (759K) | (8K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (254K) | (197K) | (360K) | (759K) | (8K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 129K | 70.5M | 472.75M | 450M | 596.26M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 200M | 385K | (318K) | 4.49M | (504K) |
| Financing Cash Flow | 200.13M | 70.89M | 472.43M | 454.49M | 595.76M |
| Effect of Forex Changes | (92K) | 220K | 993K | 747K | (299K) |
| Net Change in Cash | 93.67M | (117.29M) | 258.83M | 78.61M | 188.14M |
| Free Cash Flow | (106.37M) | (188.39M) | (214.59M) | (376.63M) | (407.32M) |
Free Cash Flow
Net Income to FCF bridge
FY2026
= Net Income-$505.6M
+ D&A$409.0K
+ Stock-Based Comp$55.7M
+ Deferred Tax$0
+ Working Capital$42.1M
+ Other Non-Cash$99.0K
= Operating Cash Flow-$407.3M
- Capex-$8.0K
= Free Cash Flow-$407.3M
Analysis
FY2026 free cash flow is -$407.3M. FCF conversion is 80.6% of net income. Operating cash flow was -$407.3M, with capex of -$8.0K. The largest bridge item is Stock-Based Comp at $55.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| S-3ASR | S-3ASR filing | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 30, 2026 |
Does IMVT generate free cash flow?
Immunovant, Inc. (IMVT) generated -$407.32M of free cash flow in fiscal 2026.
How much operating cash flow does IMVT produce?
Operating cash flow was -$407.31M, before capital expenditures of $8,000.00.
Continue the stock analysis
Jump to another research area for this company.